Graticule Asia Macro Advisors LLC
Position in DNLI — Denali Therapeutics Inc.
CIK 1619390
NEW YORK, NY
Position in DNLI
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$56,738
New position
Shares Held
2,206
first reported quarter
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#209
of 290 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Graticule Asia Macro Advisors LLC holds $820,150 across 12 Biotechnology names. DNLI ranks #6 (6.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | TVTX |
Travere Therapeutics, Inc.
|
3,439 | $195,369 | |
| 2 | INCY |
Incyte Corp
|
1,479 | $167,659 | |
| 3 | IONS |
Ionis Pharmaceuticals Inc
|
1,264 | $100,222 | |
| 4 | EXEL |
Exelixis, Inc.
|
1,651 | $89,830 | |
| 5 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
158 | $84,838 | |
| 6 | DNLI |
Denali Therapeutics Inc.
This page
|
2,206 | $56,738 | |
| 7 | LGND |
Ligand Pharmaceuticals Inc
|
111 | $35,085 | |
| 8 | PTGX |
Protagonist Therapeutics, Inc
|
260 | $31,870 |
All Filings in DNLI
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $56,738 | 2,206 | Shares | Sole | 2026-08-12 | |
| No filing history on record for this holder in this stock. | ||||||